Publications by authors named "K Chouahnia"
Article Synopsis
- A tyrosine-kinase inhibitor (TKI) is recommended as the primary treatment for non-small-cell lung cancer (NSCLC) patients with an epidermal growth-factor receptor mutation, and the effectiveness of combining it with chemotherapy (ChT) is being researched.
- A meta-analysis of four phase III trials involving 1,413 NSCLC patients indicated that the combination of EGFR-TKI and ChT resulted in significantly longer progression-free survival (PFS) and overall survival (OS) compared to EGFR-TKI alone.
- The combination treatment showed especially improved PFS for patients with brain metastases, but more research is necessary to determine which patients are most likely to benefit from this combined approach.
Article Synopsis
- Recent studies show that using stented cryopreserved aortic allografts for tracheobronchial replacement is effective, especially for patients with severe tracheal cancer.
- The study analyzed 13 patients with extensive tracheal cancer from a larger registry, focusing on their surgical outcomes and complications.
- Findings indicate that the procedure had no 30-day mortality, a high rate of complete resection, and 84.6% of patients were alive at the last follow-up, although some experienced late complications.
: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo-immunotherapy (CIT) versus chemotherapy alone (CT). All patients underwent baseline 18-FDG PET/CT before therapy between June 2016 and September 2021.
View Article and Find Full Text PDFPatients with resectable stage IIIA - N2 lung cancer represent a very heterogeneous population with variable risks of postoperative recurrence depending on the type of N2 involvement (unisite N2, multisite N2, bulky N2, extra-capsular rupture, incomplete resection…). This heterogeneity associated with the difficulty of carrying out prospective randomized studies with sufficient power in stages IIIA - 2, results in the absence of clear and consensual recommendations (except for stages IIIA - N2 resectable R0, since LungART and PORT-C studies). The objective of this article is to make an update on the place of postoperative radiotherapy in the management of stages IIIA - N2 following the publication of two recent randomized trials (PORT-C and LungART) but also compare them fort a better understanding of the current issues raised by these first published results.
View Article and Find Full Text PDFBackground: New mutational detection techniques like next-generation sequencing have resulted in an increased number of cases with uncommon mutation and compound mutations [3%-14% of all epidermal growth factor receptor (EGFR) mutations]. In rare exon 18 mutations (3%-6%), G719X and E709X represent the majority, but CMut associating these exon 18 points mutations are even rarer, making the understanding of the impact of epidermal growth factor receptor tyrosine kinase inhibitors still limited. Three generations of EGFR tyrosine kinase inhibitors (TKIs) are available to target EGFR mutations, but according to the types of mutations, the sensitivity to TKI is different.
View Article and Find Full Text PDF